TY - JOUR
T1 - Bisphosphonates and atrial fibrillation
T2 - Systematic review and meta-analysis
AU - Loke, Yoon Kong
AU - Jeevanantham, Vinodh
AU - Singh, Sonal
PY - 2009
Y1 - 2009
N2 - We identified two case-control studies, one of which found an association between bisphosphonate exposure (ever users) and atrial fibrillation (adjusted OR 1.86; 95 CI 1.09, 3.15) while the other showed no association (adjusted OR 0.99; 95 CI 0.90, 1.10). Both studies failed to demonstrate a significant association in 'current' users.We did not find a significant increase in the risk of stroke (three trial datasets; OR 1.00; 95 CI 0.82, 1.22; p0.99; I20) or cardiovascular mortality (three trial datasets; OR 0.86; 95 CI 0.66, 1.13; p0.28; I231).
AB - We identified two case-control studies, one of which found an association between bisphosphonate exposure (ever users) and atrial fibrillation (adjusted OR 1.86; 95 CI 1.09, 3.15) while the other showed no association (adjusted OR 0.99; 95 CI 0.90, 1.10). Both studies failed to demonstrate a significant association in 'current' users.We did not find a significant increase in the risk of stroke (three trial datasets; OR 1.00; 95 CI 0.82, 1.22; p0.99; I20) or cardiovascular mortality (three trial datasets; OR 0.86; 95 CI 0.66, 1.13; p0.28; I231).
UR - http://www.scopus.com/inward/record.url?scp=63849083483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63849083483&partnerID=8YFLogxK
U2 - 10.2165/00002018-200932030-00004
DO - 10.2165/00002018-200932030-00004
M3 - Article
C2 - 19338379
AN - SCOPUS:63849083483
SN - 0114-5916
VL - 32
SP - 219
EP - 228
JO - Drug Safety
JF - Drug Safety
IS - 3
ER -